Braidwell LP Esperion Therapeutics, Inc. Call Options Transaction History
Braidwell LP
- $1.63 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding ESPR
# of Institutions
198Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$14.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$12.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$11.5 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$10.2 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$7.28 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $69.9M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...